Study Title

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma

Study Details

Description:

Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier. Objective: To find out if the radiotracer 18F-fluciclovine (a substance injected into the blood during imaging scans) is better at detecting MM than the one (18F-FDG) currently used for this purpose.

Sponsor:

National Cancer Institute

Contacts:

NCI Medical Oncology Referral Office

ncimo_referrals@nih.gov

(888) 624-1937

Elizabeth M Hill, M.D. (Principal Investigator)

elizabeth.hill@nih.gov

(240) 889-5377

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468